Clinical Trials and Research

HistoryThe subtype of TTR protein mutation, its tissue distribution, and the amount of amyloid deposition largely determine the clinical manifestations of ATTR. The…

An amyloidosis diagnosis brings a rush of questions. Where should I go? Who truly understands this disease? Are there clinical trials for someone like me? For too…

Accurate differentiation between light-chain (AL) amyloidosis and transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is critical for effective patient…

Northfield, Ill. (November 24, 2025) — A new evidence-based guideline to help standardize the diagnosis of amyloidosis and improve patient care, was just published…

The objective of this study is to determine the association of clinically prescribed, on-label, TTR stabilizing therapy (e.g. tafamidis or acoramidis) with levels…

Clinical Takeaway: Two studies show that cardiac amyloidosis is more common than we thought.ContextCardiac amyloidosis is traditionally considered to be relatively…

AbstractPurpose of Review The most common type of cardiac amyloidosis is transthyretin amyloidosis (ATTR-CM). Early forms of the disease can often go undetected.…

DelveInsight’s “AL Amyloidosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the AL Amyloidosis, historical…

Data presented at the 2024 American Heart Association (AHA) Scientific Sessions highlighted that early initiation and continuous use of acoramidis (Attruby;…

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased…